Cabaletta Bio, Inc. (CABA)

Cabaletta Bio reported its Third Quarter 2025 financial results with an EPS of -$0.44, surpassing estimates. The company completed a $100 million public offering in the second quarter of 2025, expected to extend its cash runway into the second half of 2026. As of November 21, 2025, the stock price was $2.08 per share, a decline from $2.29 on November 25, 2024, with a 52-week range of $0.986 to $5.460. Analyst ratings for Cabaletta Bio stock have predominantly been "Buy."

As a clinical-stage biotechnology company, Cabaletta Bio, Inc. does not yet have commercialized products or services, so traditional demand seasonality is not applicable. Information regarding market seasonality for CABA stock would require specialized data.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases, utilizing its CABA platform with CARTA and CAART strategies. Its major product candidates include Rese-cel, DSG3-CAART, MuSK-CAART, FVIII-CAART, PLA2R-CAART, and DSG3/1-CAART.

Cabaletta Bio, Inc. is headquartered in Philadelphia, Pennsylvania, United States, and plans to expand into international markets.

Cabaletta Bio's brand reputation has been positively influenced by the presentation of positive clinical data for rese-cel at medical meetings in October 2025, highlighting its potential for transformative clinical responses and favorable safety profile. Promising clinical data for rese-cel were also reported at the EULAR 2025 Congress, showing deep B cell depletion and clinical responses. The appointment of Steve Gavel as Chief Commercial Officer in October 2025 is also a positive step.

Cabaletta Bio's ownership is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 23.35% to 27.45% of the stock, insiders own about 1.62%, and the general public and individual investors hold approximately 19% to 70.93%. Major institutional owners include Bain Capital Life Sciences Investors, LLC, Adage Capital Partners Gp, L.L.C., Jennison Associates Llc, T. Rowe Price Investment Management, Inc., Cormorant Asset Management, LP, Vanguard Group Inc, Woodline Partners Lp, Heights Capital Management, Inc., and Blackrock, Inc.